All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition
On August 31, 2020, the U.S. Food and Drug Administration (FDA) granted fast track and orphan drug designations to VLS-101 for the treatment of patients with mantle cell lymphoma (MCL).1
VLS-101 is an antibody-drug conjugate targeting tyrosine kinase-like orphan receptor 1 (ROR1). A first-in-human, phase I, dose-escalation trial (NCT03833180) is currently investigating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of VLS-101 in patients with relapsed or refractory hematological malignancies, including MCL.
VLS-101 could represent a new therapeutic option for patients with MCL.
FDA grants priority review of zanubrutinib for R/R MCL
FDA accepted a new drug application (NDA) for zanubrutinib (BGB-3111) for the treatment of patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and granted a Priority Review...
Which emerging therapies are likely to shape treatment approaches for relapsed MCL?
During the EHA2021 Virtual Congress, the Lymphoma Hub spoke with Michael Wang, MD Anderson Cancer Center, Houston, US. We asked, Which emerging therapies are likely...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox